These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 27920501)

  • 1. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer.
    Zhang H
    Drug Des Devel Ther; 2016; 10():3867-3872. PubMed ID: 27920501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Liao BC; Lin CC; Yang JC
    Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.
    Castellanos EH; Horn L
    Curr Treat Options Oncol; 2015 Oct; 16(10):51. PubMed ID: 26364032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
    Gazdar AF
    Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
    Chen YM
    J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Pirker R
    Curr Opin Oncol; 2016 Mar; 28(2):115-21. PubMed ID: 26720671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EGFR
    Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
    Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.